Evidence map›Paper›PMID 28628843›Full record

Trial reportEuropean journal of cancer (Oxford, England : 1990)2017

Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial.

Michael Stahl, Martin K Walz, Jorge Riera-Knorrenschild, Martin Stuschke, Andreas Sandermann, Michael Bitzer, Hansjochen Wilke, Wilfried Budach

4 registry-linked trialsAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of cancer (Oxford, England : 1990), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 161 papers, 23 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
161citing papers in PubMed, 23 pooled it
23.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03734952 narecruitingnot on this mapstarted 2023, after this paper: background citation

Prospective Randomized Controlled Trial of Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy

TypeinterventionalSponsorFujian Medical University Union HospitalRan2023 to 2029Enrolled537ConditionsRadiation OncologyArmsNeoadjuvant Radiotherapy Program:, Neoadjuvant chemotherapy Program, Esophagectomy program:, Postoperative radiotherapy program
NCT05161572 phase2terminatednot on this mapstarted 2021, after this paper: background citation

A Randomized Phase II Trial of Perioperative Chemoimmunotherapy Verses Perioperative Chemoimmunotherapy Plus Preoperative Chemoradiation for Locally Advanced Gastric (G) or Gastroesophageal Junction (GEJ) Adenocarcinoma

TypeinterventionalSponsorFudan UniversityRan2021 to 2022Enrolled6ConditionsStomach Neoplasms, Esophagogastric Junction Disorder, Neoadjuvant Therapy, ChemoradiotherapyArmsOxaliplatin, Tegafur-Gimeracil-Oteracil, Sintilimab, Concurrent chemoradiation, D2/R0 gastrectomy
NCT05213312 phase2 / phase3unknown statusnot on this mapstarted 2022, after this paper: background citation

A Randomized, Multicenter, Double Blind, Phase II Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable Esophageal Squamous Cell Carcinoma

TypeinterventionalSponsorShanghai Zhongshan HospitalRan2022 to 2024Enrolled90ConditionsEsophageal Squamous Cell CarcinomaArmsNivolumab, Cisplatin, Paclitaxel, 5Fluorouracil, Esophagectomy (minimally invasive)
NCT06584435 phase2active not recruitingnot on this mapstarted 2022, after this paper: background citation

A Single-arm Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer

TypeinterventionalSponsorTianjin Medical University Second HospitalRan2022 to 2027Enrolled100ConditionsHigh-risk Renal Cell CarcinomaArmsToripalimab
3 · Its place in the literature

Who cites it

161 citing papers in PubMed, 23 syntheses or guidelines pooled it, 279 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    Guideline
  10. Pooled it
  11. Effects of neoadjuvant chemotherapyWorld journal of gastroenterology · 2024
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Evaluation of tumor regression by neoadjuvant chemotherapy regimens for esophageal adenocarcinoma: a systematic review and meta-analysis.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2023
    Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

101 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Michael StahlDepartment of Medical Oncology, Kliniken Essen-Mitte, Essen, Germany. Electronic address: m.stahl@kliniken-essen-mitte.de.
Martin K WalzDepartment of Surgery, Kliniken Essen-Mitte, Essen, Germany.
Jorge Riera-KnorrenschildDepartment of Hematology and Oncology, University of Giessen-Marburg, Marburg, Germany.
Martin StuschkeDepartment of Radiation Oncology, University of Duisburg-Essen, Essen, Germany.
Andreas SandermannWissenschaftlicher Service Pharma GmbH, Langenfeld, Germany.
Michael BitzerDepartment of Gastroenterology, University of Tübingen, Tübingen, Germany.
Hansjochen WilkeDepartment of Medical Oncology, Kliniken Essen-Mitte, Essen, Germany.
Wilfried BudachDepartment of Radiation Oncology, University Hospital of Düsseldorf, Düsseldorf, Germany.
Kliniken Essen-Mitte · DEHeinrich Heine University Düsseldorf · DEUniversitätsklinikum Gießen und Marburg · DEUniversity of Duisburg-Essen · DEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundResults of the PreOperative therapy in Esophagogastric adenocarcinoma Trial (POET) showed some benefits when including radiotherapy into the preoperative treatment. This article is reporting long-term results of this phase III study. PATIENTS AND

methodsPatients with locally advanced adenocarcinomas of the oesophagogastric junction (Siewert types I-III) were eligible. Randomisation was done to chemotherapy (group A) or induction chemotherapy and chemoradiotherapy (CRT; group B) followed by surgery.

resultsThe primary end-point of the study was overall survival at 3 years. The study was closed early after 119 patients having been randomised and were eligible. Local progression-free survival after tumour resection was significantly improved by CRT (hazard ratio [HR] 0.37; 0.16-0.85, p = value 0.01) and 20 versus 12 patients were free of local tumour progression at 5 years (p = 0.03). Although the rate of postoperative in-hospital mortality was somewhat higher with CRT (10.2% versus 3.8%, p = 0.26), more patients were alive at 3 and 5 years after CRT (46.7% and 39.5%) compared with chemotherapy (26.1% and 24.4%). Thus, overall survival showed a trend in favour of preoperative CRT (HR 0.65, 95% confidence interval [CI] 0.42-1.01, p = 0.055).

conclusionAlthough the primary end-point overall survival of the study was not met, our long-term follow-up data suggest a benefit in local progression-free survival when radiotherapy was added to preoperative chemotherapy in patients with locally advanced adenocarcinoma of the oesophagogastric junction.

Indexed as

AdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyEsophageal NeoplasmsEsophagogastric JunctionFemaleGermanyHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalProspective StudiesStomach NeoplasmsOesophagogastric adenocarcinomaPhase III trialPreoperative chemoradiotherapyPreoperative chemotherapy

Identifiers

PMID28628843
OpenAlexW2733330634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.